P2D Bioscience has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute. The purpose of this grant is to develop a novel class of anti-inflammatory drugs specifically targeting lung diseases, including acute lung injury/acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma.
Click here to read the entire release.